In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


International Murex Technologies Corp.

Division of Abbott Laboratories Inc.

Latest From International Murex Technologies Corp.

Digene's Long Road Towards a Blockbuster

After spending a decade developing its technology and product development capabilities, centered on testing for human papillomavirus, the cause of cervical cancer, Digene Corp. is growing its top line and finally gaining visibility. Now, the question is whether it can validate its test clinically and secure its market position, which means dislodging an entrenched cytology infrastructure. If successful, the company could become a superstar. On the other hand, its proprietary position could be undermined by other cervical cancer markers that appear downstream of initial HPV infection and have a higher correlation with disease. And Digene's focus on the HPV product opportunity has limited its efforts in developing its core technology at a time when other companies are dedicating significant resources to similar efforts.

Medical Device Platform Technologies

Chiron and Roche Bury the Hatchet--for Now

After years of jousting over Chiron's HCV patents, Chiron and Roche have finally come to an agreement, or at least a partial agreement--with implications for anyone working with HCV and HIV testing. Chiron, in exchange for licensing HCV and HIV to Roche for diagnostic purposes, will receive up to $115 million from Roche, not counting future royalties. But their disagreement over rights to HCV and HIV for blood screening has yet to be resolved.

Medical Device Legal Issues

Innogenetics on its Own

Innogenetics, like many biotech companies, has built a diagnostics business in order to capture short-term revenues. But it got squeezed by industry consolidation and its response is an aggressive and expensive strategy to increase its emphasis on high-margin, novel tests, which it will use to fund conversion to a direct sales and marketing network in major markets.

BioPharmaceutical Medical Device

Have Problem? Try M&A.

M&A was the universal prescription for the medical industry in 1998 as acquisition dollar volumes hit record levels. For some, the dealmaking further separates the haves and have-nots. For others, it's an addictive drug for coping with chronic insufficiency syndrome. But for nearly everyone who's using it, M&A is the easiest, if not always an effective, answer to the increasingly intractable problem of growth.

BioPharmaceutical Medical Device
See All

Company Information

  • Industry
  • In Vitro Diagnostics
  • Therapeutic Areas
  • Infectious & Viral Diseases
  • Alias(es)
  • Ownership
  • Headquarters
  • Worldwide
    • North America
      • Canada
  • Parent & Subsidiaries
  • Abbott Laboratories Inc.
  • Senior Management
  • Richard D Strayer Jr., CFO
    David Schaefer, General Mgr., Mktg. & Strategic Planning
  • Contact Info
  • International Murex Technologies Corp.
    Phone: (519) 836-8016
    2255 B. Queen St. E
    Ste. 828
    Toronto, ON M4E 1G3